Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure

NCT01982292 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

321

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Heart Failure

Interventions

DRUG: RLX030 (serelaxin)
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals